stoxline Quote Chart Rank Option Currency Glossary
  
Minerva Neurosciences, Inc. (NERV)
2.355  -0.035 (-1.46%)    05-30 15:25
Open: 2.39
High: 2.4693
Volume: 22,648
  
Pre. Close: 2.39
Low: 2.32
Market Cap: 16(M)
Technical analysis
2024-05-30 3:16:14 PM
Short term     
Mid term     
Targets 6-month :  2.91 1-year :  3.04
Resists First :  2.49 Second :  2.6
Pivot price 2.47
Supports First :  2.31 Second :  1.92
MAs MA(5) :  2.43 MA(20) :  2.45
MA(100) :  4.55 MA(250) :  6.18
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  26.5 D(3) :  35.8
RSI RSI(14): 39.1
52-week High :  13.48 Low :  2.28
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NERV ] has closed above bottom band by 9.3%. Bollinger Bands are 91.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.5 - 2.51 2.51 - 2.52
Low: 2.34 - 2.36 2.36 - 2.37
Close: 2.38 - 2.41 2.41 - 2.43
Company Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Headline News

Wed, 29 May 2024
Can the Rally in Minerva Neurosciences (NERV) Shares Continue? - Yahoo Movies UK

Wed, 29 May 2024
Minerva Neurosciences (NERV) Enters Overbought Territory - Yahoo Movies UK

Mon, 27 May 2024
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics ... - Yahoo Movies UK

Mon, 27 May 2024
NERV INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit has been Filed ... - Marketscreener.com

Sun, 26 May 2024
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World

Mon, 06 May 2024
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 7 (M)
Shares Float 5 (M)
Held by Insiders 22.2 (%)
Held by Institutions 35.8 (%)
Shares Short 26 (K)
Shares Short P.Month 40 (K)
Stock Financials
EPS -4.43
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -5.24
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -30 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.5
Qtrly Earnings Growth 0 %
Operating Cash Flow -21 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.54
PEG Ratio 0
Price to Book value -0.46
Price to Sales 0
Price to Cash Flow -0.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android